Eton Pharmaceuticals (NASDAQ:ETON) Earns “Buy” Rating from HC Wainwright

Eton Pharmaceuticals (NASDAQ:ETON)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $33.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 124.80% from the stock’s current price.

ETON has been the topic of a number of other reports. Craig Hallum increased their target price on Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. B. Riley assumed coverage on shares of Eton Pharmaceuticals in a research report on Friday, January 10th. They issued a “buy” rating and a $21.00 price target on the stock.

Eton Pharmaceuticals Trading Down 4.0 %

Shares of NASDAQ ETON opened at $14.68 on Wednesday. The stock has a market cap of $382.43 million, a P/E ratio of -66.73 and a beta of 1.37. The stock has a 50 day moving average of $15.45 and a two-hundred day moving average of $11.42. Eton Pharmaceuticals has a twelve month low of $3.03 and a twelve month high of $18.41.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02). Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. The company had revenue of $11.65 million for the quarter, compared to analyst estimates of $10.53 million. As a group, research analysts predict that Eton Pharmaceuticals will post -0.14 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. acquired a new position in Eton Pharmaceuticals in the third quarter valued at about $54,000. Tower Research Capital LLC TRC bought a new stake in shares of Eton Pharmaceuticals during the 4th quarter valued at $86,000. Jane Street Group LLC bought a new stake in shares of Eton Pharmaceuticals during the 3rd quarter worth $90,000. Jefferies Financial Group Inc. bought a new stake in shares of Eton Pharmaceuticals during the 4th quarter worth $133,000. Finally, Raymond James Financial Inc. bought a new position in Eton Pharmaceuticals in the fourth quarter valued at about $147,000. Institutional investors own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.